News >

Atezolizumab/Cobimetinib Combo Misses PFS Endpoint in BRAF V600 Wild-Type Melanoma

Gina Columbus
Published: Friday, Jun 21, 2019

The combination of atezolizumab (Tecentriq) and cobimetinib (Cotellic) did not improve progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients with previously untreated BRAF V600 wild-type melanoma, missing the primary endpoint of the phase III IMspire170 trial (NCT03273153).1

Treatment-related grade 3/4 AEs occurred in 54.5% of patients, which comprised diarrhea (13.6%) and dermatitis acneiform (9.1%) as the most common events. There were no related grade 5 AEs. Treatment-related serious AEs occurred in 13.6% of patients, all of which found to be manageable. There was one patient who discontinued treatment due to an AE.

References

  1. United States Securities and Exchange Commission: Form 8-K. Exelixis. Published June 19, 2019. https://bit.ly/2L5xOuW. Accessed June 21, 2019.
  2. Miller WH, Kim TM, Lee CB, et al. Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity. J Clin Oncol. 2017;35(suppl; abstr 3057). doi: 10.1200/JCO.2017.35.15_suppl.3057.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x